Home / Patient Care / COVID-19 Outpatient Therapeutics
COVID-19 Outpatient Therapeutics
General Information for Patients
Stanford Health Care is offering COVID-19 therapeutics for treatment or prevention in eligible patients, whether within or outside of the Stanford Health Care system, in accordance with national guidelines.
Due to the evolving variants and supply of medications, Stanford Health Care will select the specific therapeutic based individual patient factors.
To learn more about currently recommended therapeutics, please visit https://www.covid19treatmentguidelines.nih.gov/ or talk to your doctor.
Request to be screened for treatment:
For pre-exposure prophylaxis, talk to your provider to initiate a referral.
Treatment of Mild-Moderate COVID-19 – Jan. 19, 2022
Depending on age, health history, and duration of COVID-19 symptoms, you may qualify for a treatment for the infection.
The most current treatments offered can be found in the patient self-referral form.
Post-exposure prophylaxis – Jan. 19, 2022
For COVID-negative patients to prevent infection after exposure to a COVID positive individual.
No monoclonals active against the omicron variant are available for post-exposure prophylaxis.
Pre-exposure prophylaxis – March 4, 2022
For COVID-negative patients to prevent infection before exposure to a COVID positive individual.
Recently, Evusheld, a combination of tixagevimab and cilgavimab, received emergency use authorization for pre-exposure prophylaxis to prevent COVID-19 in patients who have moderate to severe immune compromise due to a medical condition or have received immunosuppressive medicines or treatment and may not mount an adequate immune response to COVID-19 vaccination. Patients should contact their provider to initiate a referral.
Eligibility Requirements
- Test positive for COVID-19
- Be less than 7 days from onset of symptoms
- Meet one or more high-risk criteria (see below)
High-risk criteria
- Over 65 years old
- Over 55 years old with comorbidities such as cardiovascular disease, high blood pressure, COPD or other chronic respiratory disease
- Over 18 years old with comorbidities such as diabetes, immunosuppressive disease, chronic kidney disease, congenital heart disease, pregnancy, or obesity (elevated BMI)
- Patients who are unlikely to respond to the COVID-19 vaccine due to immune compromise or have had a severe reaction to a COVID-19 vaccine
- No COVID-19 related symptoms or recent exposure to COVID-19
Instructions for Appointment
While in the treatment center, you must keep your mask on the entire time and not have anything to eat or drink. Bathroom facilities are available.
If you have questions, please call at 650-391-8503. A member of the COVID Outpatient Therapeutics Clinic will respond to your call.
Locations
(additional treatments sites may be available)
Hoover Medical Pavilion
Infusion Center
211 Quarry Road, 2nd Floor
Palo Alto, CA 94304
Are you a health care provider?
Frequently Asked Questions
Monoclonal antibodies are investigational because they are still being studied. There is limited information known about the safety or effectiveness of using monoclonal antibody treatment to treat or prevent COVID-19.
The FDA has authorized the emergency use of monoclonal antibody treatment for the treatment of COVID-19 under an Emergency Use Authorization (EUA).
To learn more about the benefits of the monoclonal antibody therapy visit the Health and Human Services website.
Monoclonal antibody treatment is an investigational therapy used to treat mild to moderate symptoms of COVID-19 in non-hospitalized adults and adolescents (12 years of age and older who weigh at least 88 pounds (40 kg)), and who are at high risk for developing severe COVID-19 symptoms or the need for hospitalization.
Monoclonal antibodies may prevent COVID-19 infection in patients who do not respond to COVID-19 vaccines due to their weakened immune systems. They may also prevent COVID-19 infection in patients who cannot receive COVID-19 vaccination due to a past allergic reaction.
There are several monoclonal antibody treatments available to treat or prevent COVID-19. Your healthcare provider will select the therapy that is available and most effective against the current COVID-19 virus. You will be given more detailed information about the specific medication at the time that you receive therapy.
Tell your health care provider about all of your medical conditions, including if you:
- Have any allergies
- Are pregnant or plan to become pregnant
- Are breastfeeding or plan to breastfeed
- Have any serious illnesses
- Are taking any medications (prescription, over-the-counter, vitamins, and herbal products)
- Have any bleeding disorder or are taking medications that increase your risk of bleeding
- Have any heart conditions
- For treatment of COVID-19, Monoclonal antibody treatment is given to you either through a vein (intravenous or IV) or by injection into a muscle (intramuscular or IM).
- Your health care provider will determine the specific monoclonal antibody .
- You will be monitored by a nurse for one hour after the injection.
- Other potential treatment options for mild to moderate COVID-19 in non-hospitalized patients include Paxlovid (nirmatrelvir/ritonavir), molnupiravir, remdesivir.
- Go to covid19treatmentguidelines.nih.gov for information on the emergency use of other medicines that are not approved by the FDA to treat people with COVID-19. Your health care provider may talk with you about clinical trials you may be eligible for.
- It is your choice to be treated or not to be treated with monoclonal antibodies. Should you decide not to receive monoclonal antibody treatment or stop it at any time, it will not change your standard medical care.
Tell your health care provider right away if you have any side effect that bothers you or does not go away. Report side effects to FDA MedWatch at fda.gov/medwatch or call 1-800-FDA-1088 (1-800-332-1088).
The monoclonal antibody treatment will be provided with no out-of-pocket cost to patients.
The actual medication is free of charge. However, there is a cost to administer the medication. This cost will be billed and paid by your insurance or government program. As part of the standard practice by your insurance provider, they may send you a notice indicating that you may owe some amount of money to Stanford Health Care for the treatment. However, Stanford Health Care will not bill you directly, and there’s no out-of-pocket cost to you to get the monoclonal antibody treatment.
- Ask your health care provider.
- Visit Health and Human Services.
- Contact your local or state public health department.
- The United States FDA has made monoclonal antibody treatment available under an emergency access mechanism called an EUA. The EUA is supported by a Secretary of Health and Human Services' (HHS) declaration that circumstances exist to justify the emergency use of drugs and biological products during the COVID-19 pandemic.
- Monoclonal antibody treatment has not undergone the same type of review as an FDA approved or cleared product. The FDA may issue an EUA when certain criteria are met, which includes that there are no adequate, approved, and available alternatives. In addition, the FDA decision is based on the totality of scientific evidence available showing that it is reasonable to believe that the product meets certain criteria for safety, performance, and labeling and may be effective in treatment of patients during the COVID-19 pandemic. All of these criteria must be met to allow for the product to be used in the treatment of patients during the COVID-19 pandemic.
- The EUA for monoclonal antibody treatment is in effect for the duration of the COVID-19 declaration justifying emergency use of these products, unless terminated or revoked (after which the product may no longer be used).